Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.53 |
| ▸ | HTR2A | P28223 | 14/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.52 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740357 | 0.84 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL31351537 | 0.80 | PYCR1 (0.42) | SLC6A4KCNH2HTR2ASLC6A2PYCR1 | |
| SCHEMBL29875226 | 0.79 | SLC6A4 (0.56) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL2569349 | 0.79 | SLC6A4 (0.56) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL28879829 | 0.79 | SLC6A4 (0.47) | SLC6A4KCNH2HTR2ASLC6A2PYCR1 | |
| SCHEMBL30435034 | 0.78 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL8279448 | 0.78 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL3591332 | 0.78 | HTT (0.59) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL257088 | 0.77 | PYCR1 (0.50) | SLC6A4KCNH2HTR2ASLC6A2PYCR1 | |
| SCHEMBL31378001 | 0.76 | SLC6A4 (0.36) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3565811-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3517112-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1838315-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | sanofi-aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074813-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI-AVENTIS (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SLC6A4 4408/4885KCNH2 4739/4885HTR2A 2251/4885 |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | SLC6A4 374/4885KCNH2 294/4885HTR2A 379/4885 |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | SLC6A4 4408/4885KCNH2 4739/4885HTR2A 2251/4885 |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | SLC6A4 84/4885KCNH2 572/4885HTR2A 1017/4885 |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SLC6A4 4408/4885KCNH2 4739/4885HTR2A 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.